Ayala Pharmaceuticals Inc (fka ADXS)

[ignatiusrielly35]

I understand the logic, Blue. My only thought is that bluffing Amgen with selling off HOT indications is one thing. Actually licensing the parts to multiple BPs could make a buyout less attractive to Amgen. The other BPs get the majority of future profits, not ADXS. Amgen may not be that interested in only buying ADXS’s future HOT royalties.